Compliance updated on Jun 19, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

Imugene Ltd

IMU.AX ✓ COMPLIANT ☆ Track — members

ASX · Healthcare · Biotechnology & Medical Research ·

Australia Micro Cap Analyst: BUY

Last Close

$0.06

▼ -1.20%

Market Cap $28.33M · Vol 455.17K

Key Metrics

P/E Ratio

N/A

FWD: N/A

Market Cap

$28.33M

Micro Cap

Div Yield

N/A

Semi-annual dividend

EPS Growth

-494.13%

YoY

RSI (14)

30.00

Momentum

Beta

1.96

vs Market

52W High

$0.33

80.74% below

52W Low

$0.06

1.65% above

Volume

455.17K

Avg 2.88M

P/B

2.16

Price-to-book

ROE

N/A

Return on equity

Free Float

89.72%

Public shares

Shariah Compliance8 STANDARDS

✓ Yes, Imugene Ltd (IMU.AX) stock is Shariah compliant

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See the verdict under each standard, the exact screening ratios, purification and zakat per share. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does IMU.AX pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

-3.53%

-15.46%

-11.83%

-67.84%

YTD

-77.53%

-72.20%

-97.19%

-99.17%

Financials & Valuation

TTM · Annual

Total Revenue	$0.00
Net Income	$-45,416,125.00
Revenue Growth (YoY)	N/A
Gross Margin	N/A
Operating Margin	N/A
Net Profit Margin	N/A
ROE	N/A
ROA · ROIC	-58.75% · N/A

P/E Ratio	N/A
Forward P/E (FY1)	N/A
PEG Ratio	N/A
P/S	N/A
P/B	2.16
P/FCF	N/A
EPS Growth	-494.13%
Outstanding Shares	489.72M

Technical Indicators

50-Day SMA	$0.07
200-Day SMA	$0.14
RSI (14)	30.00
Beta	1.96
52-Week High	$0.33
52-Week Low	$0.06

Volume Today	455.17K
Avg Daily Volume (30D)	2.88M
Relative Volume	0.16x
Volatility (10D)	23.80
Volatility (30D)	77.57
Free Float	89.72%

Analyst Consensus

BUY

Current Price $0.06

Mean Target $0.24

52W Low$0.06 52W High$0.33

Current

Target

$0.06 $0.33

Current Analyst target

+310.71% upside potential · 3 analysts

Identifiers

ExchangeASX

FIGIBBG001S7H440

ISINAU000000IMU9

CountryAustralia

Sub-IndustryBiotechnology & Medical Research (NEC)

Earnings DateAug 28, 2026

TypeStocks

Instrument TypeFULLPAID Fully Paid Ordinary

Similar Halal Stocks

LONN.S Lonza Group AG -1.78% RVMD Revolution Medicines Inc +0.85% ONC BeOne Medicines AG -2.40% 068270.KS Celltrion Inc -0.50% ABVX Abivax SA -2.05%

Company Profile

Imugene Limited is a clinical-stage immune-oncology company. It is engaged in developing a range of new and novel immunotherapies that seek to activate the immune system of cancer patients to treat and eradicate tumors. Its platform technology seeks to harness and promote the body’s immune system against cancerous tumors. Its product pipeline includes an off-the-shelf (allogeneic) cell therapy CAR T drug Azer-Cel (azercabtagene zapreleucel) which targets CD19 to attack blood cancer. Its pipeline includes an Oncolytic Virus and B-Cell Immunotherapies aimed at treating a variety of cancers in combination with standard of care drugs and immunotherapies. Its lead candidate is a chimeric vaccinia (pox) virus known as CF33, which is a combination of genomic sequences from multiple vaccinia virus strains to generate a new, safer and more potent virus. Its Chimeric antigen receptor (CAR)-engineered T cells (CAR T) are T cells redirected against tumors through engineered expression of CARs.